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Imaging Parkinson’s disease below the neck
Per Borghammer1, Karoline Knudsen1, Tatyana D. Fedorova1 and David J. Brooks1,2,3
Parkinson’s disease is a systemic disorder with widespread and early α-synuclein pathology in the autonomic and enteric nervous
systems, which is present throughout the gastrointestinal canal prior to diagnosis. Gastrointestinal and genitourinary autonomic
symptoms often predate clinical diagnosis by several years. It has been hypothesized that progressive α-synuclein aggregation is
initiated in hyperbranched, non-myelinated neuron terminals, and may subsequently spread via retrograde axonal transport. This
would explain why autonomic nerves are so prone to formation of α-synuclein pathology. However, the hypothesis remains
unproven and in vivo imaging methods of peripheral organs may be essential to study this important research ﬁeld. The loss of
sympathetic and parasympathetic nerve terminal function in Parkinson’s disease has been demonstrated using radiotracers such as
123I-meta-iodobenzylguanidin, 18F-dopamine, and 11C-donepezil. Other radiotracer and radiological imaging methods have shown
highly prevalent dysfunction of pharyngeal and esophageal motility, gastric emptying, colonic transit time, and anorectal function.
Here, we summarize the methodology and main ﬁndings of radio-isotope and radiological modalities for imaging peripheral
pathology in Parkinson’s disease.
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INTRODUCTION
Parkinson’s disease (PD) is a systemic disorder with widespread α-
synuclein pathology in the peripheral and enteric nervous
systems.1 Extensive pathology is seen in the parasympathetic
and sympathetic nervous system and throughout the gastro-
intestinal canal in diagnosed PD cases and in the prodromal
disease phase.2–6 Genitourinary and gastrointestinal autonomic
symptoms also predate clinical diagnosis.7–9 It has been hypothe-
sized that α-synuclein aggregation is initiated in hyperbranched,
non-myelinated neuron terminals, and subsequently spreads via
retrograde axonal transport. This hypothesis would also explain
the predisposition of autonomic nerves to form early and severe
α-synuclein pathology.10, 11
Functional imaging tools are important for elucidating the
nature and chronology of peripheral pathology in PD. Radio-
isotope studies have the ability to directly assess the loss of
cellular structures, including parasympathetic and sympathetic
nerve endings. Other imaging methods can determine the
functional consequences of these pathologies. Dysphagia, gastric
emptying, intestinal transit times, and anorectal dysfunction can
all be quantitated through the use of radiotracer and radiological
imaging techniques. Here, we summarize the methodology and
main ﬁndings of these diverse methods for imaging the periphery
in PD.
IMAGING THE SYMPATHETIC NERVOUS SYSTEM
The sympathetic post-ganglionic nerve terminals can be visualized
with the norepinephrine analogue 123I-meta-iodobenzylguanidin
(MIBG). The tracer accumulates and is stored in the vesicles of
sympathetic terminals, and is therefore an in vivo marker of
sympathetic terminal integrity. Other tracers for imaging
sympathetic terminals include the PET ligands 18F-
ﬂuorodopamine and 11C-meta-hydroxyephedrine (HED).12, 13
In the majority of PD patients, α-synuclein pathology is seen in
sympathetic ganglia and the intermediolateral column of the
medulla.2, 14 It has been shown that α-synuclein initially
accumulates in distal, cardiac sympathetic axons, followed by
proximal accumulation in the neuronal cell bodies.15 The density
of ganglionic α-synuclein inclusions is greater than in the
intermediolateral column.14 Therefore, it has been suggested that
a distal-to-central spreading sequence of α-synuclein aggregates
occurs in the sympathetic neurons.
Cardiac imaging
Sympathetic cardiac imaging in PD has been the subject of several
recent reviews,16–18 and will be only brieﬂy summarized here. An
early (15 min) and late (3–4 h) MIBG image is acquired using a
gamma camera. The images are interpreted by qualitative visual
inspection and a heart-to-mediastinum (H/M) ratio is calculated. A
nearly total loss of cardiac signal is seen in most PD patients
(Fig. 1). The purpose of early and late images is to estimate tracer
delivery and vesicular storage.19 The majority of healthy subjects
showing increasing H/M values from early to later time points,
whereas decreasing ratios are seen in most PD and DLB patients.20
In later years, several groups have shown that three-dimensional
(3D) tomographical MIBG imaging yields superior diagnostic
performance, since segmental cardiac denervation can more
easily be discerned.21, 22
Cardiac MIBG signal is reduced in 80–90% of PD and DLB
patients in total, but only in ~ 60% de novo PD patients.18, 23–26
Patients with progressive supranuclear palsy, corticobasal degen-
eration, and multiple system atrophy usually exhibit normal
cardiac innervation.20, 23 Recent meta-analyses showed overall
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sensitivity and speciﬁcity of 80–85% for differentiating PD from
atypical movement disorders.27, 28 Interestingly, nearly all RBD
patients, now known to be prodromal PD or DLB in the majority of
cases,29 show decreased cardiac MIBG uptake more similar to later
stage PD patients, and clearly surpassing the signal reduction seen
in newly diagnosed PD patients without RBD.30, 31 A recent 11C-
HED PET study demonstrated that PD patients with mildly affected
baseline scans showed progressive decline preferentially in infero-
lateral segments. In contrast, patients with severely denervated
infero-lateral wall segments at baseline showed progressive signal
loss in the anterior and septal segments, suggesting a pattern of
“catch-up” eventually leading to global left ventricle
denervation.13
Decreased cardiac MIBG uptake is more pronounced in akinetic-
rigid PD patients compared to tremor-predominant patients.32
However, the relationship between cardiac denervation and
disease stage is controversial. Some studies showed correlations
between cardiac MIBG signal and Hoehn and Yahr (H&Y) stage
and also with progressive Uniﬁed Parkinson's Disease Rating Scale
motor scores, whereas other studies failed to detect such
correlations.16
Orthostatic hypotension is common in medicated PD patients,33
but it shows limited correlation with cardiac MIBG signal.
Especially early PD cases with pathological heart scans often
show no signs of orthostatic hypotension.34–36 In a ﬂuorodopa-
mine PET study, while all PD patients with orthostatic hypotension
showed diffusely decreased myocardial uptake, 50% of those
without orthostatic hypotension showed some ﬂuorodopamine
retention primarily in the septum,37 suggesting a potential
relationship between the sympathetic imaging markers and
orthostatic hypotension. This may only be discernible when 3D
tomographic imaging is employed.
It should be noted that loss of cardiac sympathetic signal is not
speciﬁc to PD. Diabetic patients with cardiac autonomic neuro-
pathy38 and patients with chronic heart failure39 exhibit similar
reductions in cardiac MIBG signal. Furthermore, a range of
medications are known to affect MIBG uptake, including certain
antidepressants, phenylephrine, cocaine, labetalol, and other
drugs,40 and it is recommended that patients abstain from these
medications prior to MIBG imaging.
Imaging other regions
The thyroid gland is clearly discernible on a normal MIBG image
(Fig. 1a), and the thyroid is heavily innervated by sympathetic
nerves.41 Marked reductions in thyroid uptake of 18F-ﬂuorodopa-
mine and MIBG have been reported in PD patients37, 42 (Fig. 1b).
Interestingly, two studies reported similar reductions in cardiac
MIBG uptake of PD patients, heart failure patients, and diabetic
patients with neuropathy, but only the PD patients displayed a
reduction in thyroid uptake.38, 43 These ﬁndings suggest that
thyroid sympathetic denervation may be more speciﬁc for PD, and
may enhance the speciﬁcity of MIBG imaging for correctly
diagnosing PD.
No reduction was seen in uptake of MIBG by the liver or lungs in
PD.42 To our knowledge, it has not be determined whether MIBG
liver signal reﬂects its sympathetic innervation, or rather non-
speciﬁc liver accumulation of the tracer and its metabolites in the
process of tracer clearance. Some MIBG signal is always seen in the
pulmonary tissue (Fig. 1), but the observation that reserpine-
treated rodents displayed increased MIBG uptake in the lung with
concomitant decrease in heart uptake suggests that the
pulmonary MIBG uptake is non-speciﬁc.44
To summarize, moderate-to-late stage PD cases and nearly all
DLB patients show reduced cardiac accumulation of MIBG and
ﬂuorodopamine, as do most RBD patients. In contrast, only ~ 60%
of de novo PD cases show measurable sympathetic denervation,
an observation, which underscores that RBD is a unique PD
phenotype. Also, the sizeable fraction of early stage PD patients
with normal cardiac MIBG signal somewhat limits the clinical
utility of this imaging modality. Some investigators reported
correlations between motor symptom severity and loss of cardiac
MIBG signal, but cardiac sympathetic denervation on imaging
displays limited correlation with autonomic symptoms. Reduced
MIBG and ﬂuorodopamine uptake is also detectable in the thyroid
gland of most PD patients, but the clinical relevance of this
observation is uncertain.
IMAGING THE PARASYMPATHETIC NERVOUS SYSTEM
It has been suggested that PD initiates in the autonomic nerve
endings in the gastro-intestinal mucosa, perhaps induced by a
hitherto unknown toxin, which sets in motion a cascade of
pathological events.45 The disease process may then spread
through the vagal nerve from the gastrointestinal tract to the
central nervous system (CNS).
This hypothesis would explain the observation that the dorsal
vagal motor nucleus (DMV) is the primary target structure in the
brain stem of most PD patients.46 The idea is also supported by
the common ﬁnding of phosphorylated α-synuclein inclusions in
the vagus nerve2 and the ~ 50% neuron loss in the DMV of PD
patients.47, 48 In the periphery, α-synuclein aggregates are seen in
vagal efferents of internal organs,49–51 including the intestinal
myenteric and submucosal plexus.52–54 The severity of α-synuclein
pathology in the gastro-intestinal tract exhibits a rostro-caudal
gradient, with the highest density of Lewy pathology in the upper
gut,2 a distribution which correlates with vagal innervation of the
gut.55
These ﬁndings support the hypothesis that the parasympathetic
nervous system is among the ﬁrst sites to be affected in PD. The
ﬁndings also suggest that disease progression from the periphery
to central structures may partly follow parasympathetic neuronal
pathways, although this hypothesis remains unproven. Of note,
two independent epidemiological studies recently showed that
total truncal vagotomy reduces the subsequent risk of PD by
Fig. 1 123I-MIBG SPECT images superimposed on anatomical CT. a Healthy subject with normal cardiac uptake. b PD patient with severely
decreased cardiac uptake. [h heart, m mediastinum]
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40–50% (refs 56, 57), which emphasizes the important role of the
parasympathetic nervous system in the understanding of PD
pathogenesis. In vivo imaging of parasympathetic integrity in PD
could thus provide a unique insight into disease pathophysiology
as well as an improved understanding of disease initiation and
progression.
Cholinergic in vivo imaging of central brain structures in
dementia disorders has been used for many years58 and PET and
SPECT ligands are available for several molecular targets. Pre-
synaptic targets include the vesicular acetylcholine transporter
(VAChT) and the breakdown enzyme acetylcholinesterase (AChE).
Post-synaptic targets are the muscarinic and nicotinic acetylcho-
line receptors, which are abundantly expressed in the brain.58
However, despite longstanding availability of radiotracers with
afﬁnity for cholinergic targets almost no research has been done
in the ﬁeld of parasympathetic imaging—possibly since para-
sympathetic neurons do not express speciﬁc molecular targets to
distinguish them from other cholinergic connections.
Historically, studies have assessed the integrity of parasympa-
thetic, cholinergic pathways in peripheral tissue using measure-
ments of AChE activity.59–61 This method has now largely been
replaced by VAChT immunohistochemistry, which is more speciﬁc
for cholinergic neurons in general, but is also not speciﬁc for
parasympathetic ﬁbers. In the gut, more than 50% of enteric
neurons are cholinergic.21 Parasympathetic imaging of internal
organs poses an additional challenge in the form of rapid hepatic
metabolism and subsequent biliary excretion of many radio-
tracers. Thus, radio metabolites in the intestinal lumen may bias
imaging results of the gut and neighboring organs. For this
reason, radiotracers with slow biliary excretion or exclusively renal
excretion are mandatory.
The PET tracer [11C] donepezil has been successfully utilized to
measure AChE density in the brain of patients with Alzheimer’s
disease or PD.62, 63 We recently implemented this tracer for
quantiﬁcation of AChE density in peripheral organs of healthy
individuals and showed that the distribution of [11C] donepezil
approximates vagal innervation of the internal organs.64 Two [11C]
donepezil PET studies of 12 early-to-moderate stage PD patients
and 19 newly diagnosed patients have been performed. In the
early-to-moderate PD group (disease duration 4.5 years) the PET
signal was markedly decreased in the small intestine (35%)
(Fig. 2a) and pancreas (30%) compared with healthy controls.65 In
this ﬁrst study, the colon was not assessed. In contrast, newly
diagnosed PD patients (duration ~ 1 year) displayed a less
pronounced decrease of 14 % in the small intestine, no decrease
in pancreatic signal, but a signiﬁcant 22% decrease in the colon.66
These ﬁndings suggest variable rates of progression in different
internal organs, with the colon being the most severely affected,
followed by the small intestine, and then the pancreas (Fig. 2b).
However, this hypothetical progression needs to be demonstrated
in longitudinal PET studies of PD patients and ideally also RBD
patient cohorts. It should also be noted that although
11C-donepezil shows no biliary excretion during a 60min PET
scan, we observed some direct trans-mural tracer excretion across
the stomach mucosa, which may bias correct estimates of the
intestinal PET signal.66 Thus, a future research goal would be the
identiﬁcation of a cholinergic PET tracer complete free from biliary
or trans-mural excretion.
FUNCTIONAL IMAGING OF THE GASTROINTESTINAL TRACT
The full spectrum of gastrointestinal symptoms in PD was recently
reviewed in detail,67, 68 and is only brieﬂy summarized here. The
main focus in the present review will be on imaging methods
utilized for studying gastrointestinal functional alterations in PD.
Oro-pharynx and esophagus
The pooled prevalence of subjective dysphagia in PD is 35%
(ref. 69) and aspiration is also commonly seen.70 Dysphagia usually
emerges in late-stage PD, but on occasion can be the presenting
feature.71
Dysphagia may in part be caused by bradykinesia and rigidity
secondary to basal ganglia dysfunction, but the exact underlying
pathophysiology of dysphagia remains to be determined. The
esophageal motility patterns are mainly determined by nuclei in
the medulla oblongata, and vagotomy results in upper esophagus
paralysis, which impairs food propulsion.72 Theoral part of the
esophagus receives vagal innervation from the nucleus ambiguus,
whereas the distal esophagus is innervated from the DMV.73
Pathological α-synuclein inclusions are present in both of these
vagal nuclei, although much more in the DMV.46, 74 Recently, it
was shown that pathology in peripheral motor and sensory
pharyngeal nerves may also contribute to oropharyngeal
dysphagia.75
Dysphagia can be examined by ﬂuoroscopic barium studies,
where patients ingest a thin barium liquid or barium-coated bread
during a continuous X-ray.76 Oro-pharyngeal transit time and
swallowing efﬁciency can then be determined.
In a comprehensive video ﬂuoroscopy study of 72 PD patients,
epiglottic dysmotility was detected in 56% of PD patients, pharynx
constrictor dysfunction in 42%, esophagus dysmotility in 91%, and
Fig. 2 11C-donepezil PET/CT images. a Summed PET images superimposed on anatomical CT in a healthy control (top) and a PD patient
(bottom). Note the visually apparent decrease in the small intestine signal. b Hypothetical timeline of parasympathetic denervation during the
course of prodromal and manifest PD. Closed and open circles represent 11C-donepezil PET data from de novo (duration 1 year) and moderate
stage PD patients (duration 4.5 years), respectively.65, 66 Shortly after diagnosis, some 11C-donepezil signal loss is seen in the small intestine
and colon, but not in the pancreas. Five years after diagnosis, progressive signal loss is seen in the pancreas, small intestine, and colon. [l liver,
p pancreas, s small intestine]
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reﬂux in 56% (ref. 77). A similar study reported disturbances of the
oro-pharyngeal phase in 75% of PD patients.78 Silent aspiration is
also frequently seen in PD patients. More recently, a study failed to
detect perturbed swallowing function in PD patients with and
without dyskinesias compared to normal controls. Perhaps
surprisingly, the swallowing efﬁcacy was somewhat decreased in
patients without dyskinesia compared to the dyskinetic patients,
which could be caused by higher L-dopa intake in the latter
group.79
Dysphagia can also be studied using radioisotope methodol-
ogy.80 Here, the patient ingests radio-labeled water or food, the
passage of which is measured by a gamma camera. Time-activity
curves are recorded in the oropharyngeal and esophageal regions,
and the stomach. Using a combination of electromyography
(EMG) and scintigraphy, abnormal ﬁndings were detected in all of
18 PD patients, of whom only 13 complained of subjective
dysphagia. Of note, delayed esophagus transit time was the most
prevalent ﬁnding in the PD group.81
Other studies used simpler “glass of water” tests, where subjects
are timed while drinking 150mL of water. Here, 84% of PD
patients fell >1SD below and 32% of patients fell >2SD below
reference mean concerning swallowing rate (mL/s). Test perfor-
mance correlated moderately with disease duration, but poorly
with subjective symptoms of dysphagia.82 In a more detailed,
quantitative water swallowing test, 58% of the H&Y stage 1
patients and >90% of H&Y stage 2–4 patients had abnormal
results.83
To summarize, dysphagia is a frequent non-motor feature in PD,
but often displays limited correlation to objective ﬁndings.
Functional imaging studies show that most PD cases exhibit
quantiﬁable dysmotility in the oro-pharynx and esophagus.69
Importantly, esophageal dysmotility seems to be even more
prevalent than oropharyngeal dysfunction, which was further
supported by the recent ﬁnding that 62 of 65 PD patients showed
peristalsis dysfunction in the esophageal body using esophageal
high-resolution manometry.84 The high prevalence of esophageal
dysfunction may be caused by known aspects of PD pathology.
The ganglia of the distal esophageal smooth muscle receive direct
innervation from the DMV neurons, which are severely damaged
in PD.46 Also, experimental lesions of the DMV markedly impairs
motility patterns in the distal esophagus.73 Moreover, studies have
documented that the esophageal mucosa exhibits the most
extreme α-synuclein pathology throughout the gastrointestinal
canal.2, 3 The high prevalence of subjective and objective
gastroesophageal reﬂux in PD may similarly be explained by
these pathologies, since the reﬂexive relaxation and constriction
of the lower esophageal sphincter has a prominent vagovagal
component.85
Stomach
The stomach’s rhythmic contraction pattern are triggered by the
interstitial cells of Cajal.86 However, considerable modulatory input
from the autonomic and CNS is also involved in the control of
volume, contraction strength, and acid secretion.87, 88
Bloating and abdominal fullness are seen in up to 50% of PD
patients,89 and nausea and vomiting in 15% of cases.90 Whether
gastroparesis is the underlying cause of these symptoms in PD is
not fully determined. However, it seems probable that the
presence of α-synuclein inclusions in enteric neurons and in vagal
efferents to the stomach wall2, 91 is involved in perturbed gastric
motility. It was recently shown that α-synuclein transgenic mice
developed inclusion pathology in myenteric ganglia in a pattern
closely mimicking the relative distribution of vagal efferents, and
these mice developed gastroparesis and constipation.92
The solid meal scintigraphical study is considered the gold
standard for quantifying gastric emptying time (GET).93 After
ingestion of a standard meal the radioactivity is recorded by serial
images until gastric emptying is nearly complete. Figure 3 shows
representative studies of subjects with normal, rapid, and severely
delayed GET.
The presence of gastroparesis is often mentioned in the PD
literature, but only few studies used gold standard solid meal
scintigraphy to quantify GET in PD patients. One early paper
reported no difference in GET between PD patients and matched
controls.94 Another study reported that PD patients with
pronounced on–off symptoms displayed prolonged GET in
comparison to non-ﬂuctuating patients, and both patient groups
showed increased GET compared to the control group.95
Signiﬁcantly delayed GET has been reported in familial PD, but
in the same study idiopathic PD cases did not show signiﬁcantly
delayed GET.96 A recent study of 12 early stage PD patients
reported signiﬁcantly faster GET in the PD group compared to
controls.65 In a comparison between treated and untreated PD
cases, no signiﬁcant difference in emptying time was seen.97
Finally, a recent study used liquid meal scintigraphy, and only
three of 21 early PD patients showed prolonged GET.98
Thus, the majority of studies employing gold standard
scintigraphic methodology do not support that prolonged GET
is a frequent problem in PD, at least not at earlier disease stages. It
is also not resolved if the presence of delayed GET shows robust
correlations with subjective gastroparesis. The majority of studies
reported wide ranges in GET among PD patients. Indeed, in a
recent patient series two PD patients had very rapid GET (T1/2 < 30
min) indicative of a gastric dumping syndrome (Fig. 3b).65 Similar
ﬁndings were also reported by other authors.96, 97
Although not an imaging modality, GET can also be measured
with 13C-sodium breath tests. Here, a solid or liquid 13C-sodium
octanoate-containing meal is ingested, absorbed in the proximal
small intestine and converted by the liver to 13CO2. Subsequently,
the expired 13CO2 concentration is quantiﬁed and mathematically
transformed to an estimate of GET.99 The GET in PD patients has
been studied using both solid and liquid meal breath tests, and
most studies reported signiﬁcantly prolonged GET in PD patients
compared to control subjects.99–105 However, Goetze et al.100
found only signiﬁcant difference between PD and HC when using
solid meal but not with liquid meal. Recently, Epprecht et al.101
Fig. 3 Gastric emptying scintigraphy images at 0, 30, 60, and 120
min after radioactive meal ingestion. a Healthy control with normal
gastric emptying time (T1/2 72 min). The dashed line designates the
stomach. b PD patient with rapid gastric emptying time (T1/2 26
min). c Vagotomized patient with severely increased gastric
emptying time (T1/2> 180min)
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found no difference between early stage PD patients in the off
state and controls. One study of RBD patients also found no
difference compared to control subjects, suggesting that pro-
longed GET may not be a signiﬁcant prodromal feature.103
Thus, discrepant ﬁndings are seen in the studies employing
gold standard scintigraphy vs. breath test studies and this begs
the question whether 13C-sodium breath tests are representative
of gastric emptying in PD. The breath test depends on the
combination of mechanic gastric emptying, adequate small
intestine absorption and liver metabolism. The latter aspects have
received little attention in the context of PD. Two studies reported
pathological differential sugar absorption ﬁndings in PD, i.e., the
amount of recovered mannitol was decreased compared to
recovered lactulose in PD, suggesting a reduction in the
absorptive intestinal surface in PD.106, 107Another study demon-
strated increased intestinal permeability (gut leakiness) in PD.108
Nevertheless, the more consistently delayed GET in 13C-sodium
studies may be explained by the combined pathologies of
prolonged mechanical gastric emptying and small intestine
malabsorption.
Finally, functional magnetic resonance imaging (MRI) of the
stomach was able to detect a signiﬁcant reduction in the
amplitude of peristaltic contractions in PD patients, but the utility
of this measure remains to be determined.109
Small intestine
Very little is known about small intestinal function in PD. A recent
Polish study compared the small bowel transit time in ten PD
patients without gastrointestinal symptoms to ten matched
controls. All subjects ingested a capsule containing the gamma
emitting isotope 99m-technetium, which was followed using serial
SPECT imaging.110 All healthy controls had anoro-cecal transit
time <4 h, whereas seven PD patients had a transit time of >4 h
(>24 h in one patient). A small pilot trial studied colon transit time
in six PD cases using computed tomography (CT) scans and the
radio-opaque marker method and in two of these patients radio-
markers were still present in the small bowel, which is strongly
suggestive of prolonged small intestinal transit time.111
An early case study reported severely dilated small intestine in a
single PD patient.112 Interestingly, the small intestine of this
patient contained large pockets of air, which could have been
caused by small intestine anaerobic bacterial overgrowth now
known to be highly prevalent in PD.113 However, it is unknown
whether small intestine dilatation or presence of excessive
amounts of air is a common ﬁnding in PD patients.
Colon
Constipation is among the ﬁrst non-motor symptoms to emerge in
the prodromal phase of PD, appearing more than a decade before
diagnosis in a sizeable fraction of PD patients.7, 8, 114 The overall
prevalence of constipation in PD is approximately 40–50%, but
with large variation across individual studies,115–117 probably
resulting from the highly variable deﬁnitions of constipation used.
Indeed, more than ten different deﬁnitions of constipation have
been used in recent literature.118 Interestingly, the constipation
prevalence in idiopathic RBD patients may be higher compared to
PD patients without RBD.119
Widespread Lewy pathology is present in the nerve terminals of
the submucosal and myenteric colonic plexus.51, 52 The para-
sympathetic innervation to the upper colon is supplied by the
vagus, whereas the lower third is innervated by the sacral
segment of the intermediolateral column. This parasympathetic
input is intricately involved in the control of colon motility.120, 121
The parasympathetic neurons of the intermediolateral cell column
also show Lewy pathology and cell degeneration in PD.54 Onuf’s
nucleus and the lateral collateral region nucleus of the sacral
spinal cord innervates the external anal and urethral sphincters122
and also show consistent heavy Lewy pathology in diagnosed PD
cases.54, 123 The exact contribution of these multiple pathologies
to colonic symptoms and perturbed motility in PD remains to be
elucidated.
Colonic transit time (CTT) can be measured using radio-opaque
markers (ROM). Several radio-opaque plastic markers are ingested
(one per day), and an abdominal X-ray image is acquired 24 h after
the last capsule has been ingested. The CTT can then be estimated
based on the number of retained ROM (Fig. 4).124 Several studies
reported prolonged CTT in PD patients in comparison to matched
control subjects.125–128 An early report suggested that the majority
of newly diagnosed PD patients do not display prolonged CTT, but
the authors applied very stringent criteria for deﬁning prolonged
CTT in the study.129 When applying the commonly accepted cutoff
score for number of retained ROM,124 it is evident that 80% of
newly diagnosed PD patients actually display increased CTT. One
study detected no correlation between CTT and frequency of
defecations per week or subjective constipation symptoms in PD
patients. This suggests that objective CTT does not correlate with
subjective constipation.130 Another study reported no difference
Fig. 4 Radio-opaque marker studies of colonic transit time (CTT) using the 7-day (60 marker) protocol. a Healthy control with rapid CTT (4
markers). b PD patient with increased CTT (28 markers). c PD patient with severely increased CTT (57 markers). Note that the markers are
situated mostly in the descending and recto-sigmoid colon suggestive of “outlet obstruction” constipation
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in CTT between PD groups on and off levodopa treatment, which
suggests colonicdys-motility is primarily caused by pathological
processes.131
A uniform colonic distribution of markers is suggestive of slow-
transit constipation, whereas an accumulation of markers in the
distal colon is indicative of outlet-obstruction constipation
(Fig. 4c).132 This distinction is of major importance in PD, since a
substantial number of patients are unable to relax pelvic muscles
during defecation (dyssynergia).128, 133 Indeed, straining for
defecation is one of the most prevalent non-motor symptoms,
underscoring that outlet-obstruction is of major signiﬁcance in
PD.115, 134
Three studies investigated the segmental distribution of colonic
markers in PD patients. One study reported signiﬁcantly increased
rectosigmoid and total CTT in PD patients, whereas the difference
in the right and left colon was not signiﬁcant.128 Other studies
showed noticeable long recto-sigmoid transit times compared to
the other colonic segments, although they did not include control
groups for comparison.125, 131 These observations suggest that
prolonged CTT in PD is often of the “outlet obstruction” type.
Furthermore, Wang et al.125 showed that subjective symptoms of
bloating, manual evacuation of faeces, or regular use of
suppositories was much more associated with prolonged CTT
and anorectal dysfunction, than was frequency of bowel
movements.
We assessed colon volume in 24 early stage PD patients and 15
controls using CT scans, and found signiﬁcantly increased
transverse and descending colon volume in the PD group.111
Such volumetric measures may provide new insights into
gastrointestinal pathology in PD, and can be performed in a
semi-automated fashion without radiation exposure using
recently published MRI techniques.135 Also, a few early case series
demonstrated mega-colon in late stage PD patients.112, 136 Severe
dilation was seen throughout the colon but was most pronounced
in the sigmoideum and rectum, which supports that constipation
is often of the outlet obstruction type.
Recto-anal imaging
Reﬂexive propulsion in the distal colon and rectum is under the
control of lumbosacral defecation centers.137, 138 As mentioned
above, sacral parasympathetic nuclei, including the nucleus of
Onuf, exhibit consistent pathological α-synuclein inclusions in PD,
which probably contributes to defecation dyssynergia. Pathology
in more rostral centers in the CNS could, however, also be
involved.
Rectoanal dysfunction is frequent in PD and is an important
contributor to the high rate of constipation. Straining for
defecation is the most prevalent gastrointestinal symptom in PD
and is present in up to 83% of patients.115, 134, 139 One study
showed that 67% of early PD patients display defecatory problems
including straining and feelings of incomplete emptying. Impor-
tantly, only one third of these patients reported <3 bowel
movements per week, which is a commonly used deﬁnition of
constipation.140 Such symptoms of excessive straining and
incomplete emptying are indicators of outlet obstruction
constipation.132
Barium contrast defecography, in which a contrast agent is
instilled rectally, is a standard method to assess rectoanal function.
This technique provides measures of emptying rate and relaxation
of pelvic ﬂoor muscles during defecation.127, 132 Simultaneous
rectoanal manometry and EMG is often performed to measure the
pressure phases during defecation and to monitor contractile
function of the puborectalis muscle.132
An early study investigated rectoanal function in six PD cases,
who were off medication, and showed paradox contractions of the
sphincter and puborectalis muscles during straining and also
incomplete emptying, with improvement subsequent to apomor-
phine.133 Other studies reported non-signiﬁcantly increased rectal
volume, signiﬁcantly increased residual volumes after defecation,
and decreased rectal contraction in PD 128, 141 However, Edwards
et al.127 found no signiﬁcant increase in post-defecation residuals
in mild-to-moderate stage PD cases in the off state. A small study
showed that botulinum toxin injection in the puborectalis muscle
was efﬁcacious in decreasing tonus in the anorectal muscle and an
improvement in the anorectal angle was also seen during
straining. Symptom improvement was also seen in 10 of 16
patients after a period of 2 months.142
URODYNAMIC STUDIES
Imaging of the urinary bladder is rarely considered an indepen-
dent imaging modality, but rather one among several parameters
in a complete urodynamic evaluation, which also includes EMG
and pressure-ﬂow measurements during bladder storage and
micturition. For this reason, urodynamic imaging will be only
brieﬂy summarized here.
Bladder function and micturition involves numerous cortical
and subcortical structures, including prefrontal and insular cortex,
thalamus, basal ganglia, amygdala, and the periaqueductal
grey,143, 144 and it has been hypothesized that bladder dysfunc-
tion in PD mainly stems from di- and tele-encephalic patholo-
gies.144, 145 However, sympathetic and parasympathetic
preganglionic cells in the intermediolateral cell columns of the
lumbar-sacral medulla, Onuf’s nucleus, the raphe nuclei, and locus
coeruleus are also intimately involved in bladder function,122, 143
and these structures are all predilection sites for marked and early
neuronal damage in PD.54, 123 Thus, the pathophysiological
substrate of urinary dysfunction may very likely be multi-focal.
Interestingly, peripheral sympathetic denervation as measured by
123I-MIBG heart scintigraphy correlated with increasing severity of
urinary symptoms, but not with any other non-motor symptom in
PD.146
The prevalence of lower urinary tract symptoms ranges from
27% to 85% in diagnosed PD patients, and may also be increased
in idiopathic RBD.144, 147 Nocturia, frequency, and urgency are the
most prevalent bladder symptoms in PD. These symptoms are
generally suggestive of detrusor overactivity, which has been
Fig. 5 Thermograms in a healthy control subject (a) and two patients with PD (b). Note the asymmetric hand temperature in the patients.
[Figure provided at the courtesy of the Dr Antonio-Rubio and co-authors]
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corroborated in several urodynamic studies demonstrating
detrusor over activity in 40–80% of medicated PD patients,148–150
and also in 58% of de novo untreated patients.151 The bladder
volume at ﬁrst desire to void is reduced in PD,151, 152 but detrusor
activity during voiding is actually decreased in 50% of patients.149
IMAGING SKIN TEMPERATURE
The skin in PD patients shows autonomic denervation and α-
synuclein pathology can be detected in cutaneous nerve terminals
in most patients.153, 154 Thermal imaging was recently applied to
study autonomic regulation of skin temperature in PD patients for
the ﬁrst time.155 The authors reported baseline asymmetry in hand
temperature of most PD patients compared with controls (Fig. 5).
During a cold stress test, in which one hand was immersed in cold
water for 2 min, the non-immersed hand did not show a normal
cooling pattern or thermal overshoot after immersion. After
cooling the immersed hand displayed slower thermal recovery
than seen in controls. These abnormal responses differentiated PD
patients from controls with 87% sensitivity and 75–80% speciﬁcity.
CONCLUSIONS
Non-invasive imaging tools present a unique opportunity to
address the involvement of peripheral organs in PD pathophysiol-
ogy. The majority of patients display a profound loss of cardiac
sympathetic innervation. PET imaging with 11C-donepezil shows
progressive signal loss in the intestine and pancreas in early-to-
moderate stage PD, which may be a marker of parasympathetic
denervation. Various functional imaging measures provide evi-
dence for marked dysfunction throughout the gastrointestinal
system. Importantly, objective dysfunction is often considerably
more frequent than corresponding subjective symptoms. This
mismatch between symptoms and objective markers is important,
since subjective non-motor symptoms is currently utilized to
deﬁne separate PD phenotypes,156 and to diagnose prodromal
patients in the population.157 In summary, imaging measures of
peripheral dysfunction are powerful tools for improving our
knowledge of PD pathophysiology, guiding treatment, and for
enhancing the accuracy of prodromal diagnosis.
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